ΣΦ-4002

ΣΦ-4002 is a proprietary development code for a pharmaceutical candidate within the pipeline of Sigmapharm Laboratories. The company, which specializes in the development of complex generic and specialty branded drug products, identifies ΣΦ-4002 as a 'barrier-to-entry' product, suggesting it involves significant formulation, stability, or intellectual property challenges. While the specific active pharmaceutical ingredient and therapeutic indication remain undisclosed, the candidate is part of a portfolio being prepared for regulatory submission via the Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) pathways. The development of ΣΦ-4002 likely leverages Sigmapharm's proprietary drug delivery platforms, such as StereoSol-Amorphous or Particulate-UniBlend, which are designed to enhance the bioavailability and stability of challenging molecules.

Other names

Sigma-Phi-4002Sigma-Phi4002Sigma-Phi 4002